Vsmall is a brand-name medication that contains the active ingredient vildagliptin. Vildagliptin belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors, which are used to improve blood-glucose control in adults with type 2 diabetes mellitus. In Hong Kong, Vsmall is available as a 50 mg pill that requires a prescription from a qualified healthcare professional. The product is regulated by the Hong Kong Department of Health and is listed as a prescription-only medication.
Vildagliptin, the active component of Vsmall, inhibits the enzyme DPP-4. DPP-4 normally degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By blocking DPP-4, Vsmall prolongs the activity of these hormones, leading to:
The onset of action occurs within a few hours after oral intake, with peak plasma concentrations typically reached in 1-2 hours. The drug’s half-life supports once-daily dosing, and it is primarily excreted unchanged in the urine.
Vsmall is approved by the Hong Kong Department of Health for the management of type 2 diabetes mellitus in adult patients when diet, exercise, and other antihyperglycaemic agents do not provide adequate glycaemic control. It may be prescribed:
Typical candidates are adults diagnosed with type 2 diabetes who have preserved pancreatic β-cell function and no contraindications to DPP-4 inhibition.
Common side effects are typically mild and do not require discontinuation unless they persist or worsen.
Regular follow-up appointments enable dose adjustments and early detection of adverse events.
This article provides educational information about Vsmall and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Yes, Vsmall is often prescribed alongside metformin to achieve better glycaemic control. The combination targets different pathways and may improve HbA1c more than either agent alone, but dosing should be individualized by a healthcare professional.
If you remember the missed dose on the same day, take it as soon as possible. If it is close to the time of your next scheduled dose, skip the missed one and resume your regular dosing schedule. Do not double the dose.
Vsmall can be used in patients with mild renal impairment (creatinine clearance ≥ 50 mL/min) without dose adjustment. For moderate impairment, a reduced dosing interval may be recommended. Kidney function should be monitored regularly.
Both Vsmall (vildagliptin) and sitagliptin inhibit DPP-4, but they have slightly different dosing frequencies and pharmacokinetic profiles. Vsmall is typically taken once daily at 50 mg, while sitagliptin is often prescribed at 100 mg once daily. Clinical efficacy is comparable, and the choice depends on patient tolerance, cost, and prescriber preference.
Weight change is not a prominent effect of Vsmall. Clinical studies have shown neutral or modest weight loss effects, making it a suitable option for patients concerned about weight gain associated with some other antidiabetic agents.
When Vsmall is used as monotherapy, the risk of hypoglycaemia is low because its glucose-lowering effect depends on rising blood-glucose levels. However, the risk increases when combined with insulin or sulfonylureas.
Symptoms include severe upper abdominal pain that may radiate to the back, nausea, vomiting, and fever. If these occur, seek medical attention promptly, as early treatment improves outcomes.
Yes, but keep the medication in its original packaging with a clear label, and carry a copy of the prescription. In Hong Kong, Vsmall is a prescription-only drug, so you may be asked to present supporting documentation at customs.
No specific dietary restrictions are required. Maintaining a balanced diet consistent with diabetes management guidelines will support the medication’s effectiveness.
Blood-glucose reduction can be observed within the first week of therapy, with the full effect on HbA1c typically evident after 8-12 weeks of consistent use. Regular monitoring helps assess the response.
